Companies / Israel
Teva Wins Pravachol Exclusivity, Beats Chinese Patent Filings
April 2006 | Product LaunchIsrael's Teva Pharmaceutical Industries is to receive 180-day US marketing exclusivity on its generic formulation of pravastatin sodium, better known as Bristol-Myers Squibb's blockbuster hyperlipidaemia therapy Pravachol. The move follows a victory for Teva in the US District Court for the District of Columbia in a challenge brought by Canada's
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
